The co-existence of mental illness and psychoactive drug or other substance use problems — otherwise known as ‘comorbidity’ or ‘dual diagnosis’ — is an issue which has been on the radar of the EU drugs agency (EMCDDA) for over a decade (1).
Representatives of candidate, potential candidate and neighbouring countries of the EU are joining members of the EMCDDA’s Reitox network in Lisbon today for the kick-off of the agency’s fourth Reitox week.
Leading European and international experts will meet in Lisbon from 26–27 October to review the state of the art of the rapidly developing scientific area of wastewater-based epidemiology. They will be gathering at ‘Testing the waters 2017’, the third international conference on wastewater analysis, organised by the SCORE group and the EMCDDA.
It is estimated that over 1 million people receive treatment for drug-related problems in the European Union every year. How can we estimate the cost of drug treatment in Europe? This is the question explored in a new EMCDDA report released today: Drug treatment expenditure: a methodological overview.